176 related articles for article (PubMed ID: 22995087)
1. Stent thrombosis: insights on outcomes, predictors and impact of dual antiplatelet therapy interruption from the SPIRIT II, SPIRIT III, SPIRIT IV and COMPARE trials.
Kedhi E; Stone GW; Kereiakes DJ; Serruys PW; Parise H; Fahy M; Simonton CA; Sudhir K; Sood P; Smits PC
EuroIntervention; 2012 Sep; 8(5):599-606. PubMed ID: 22995087
[TBL] [Abstract][Full Text] [Related]
2. Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial.
Stone GW; Midei M; Newman W; Sanz M; Hermiller JB; Williams J; Farhat N; Caputo R; Xenopoulos N; Applegate R; Gordon P; White RM; Sudhir K; Cutlip DE; Petersen JL;
Circulation; 2009 Feb; 119(5):680-6. PubMed ID: 19171853
[TBL] [Abstract][Full Text] [Related]
3. Impact of age on clinical outcomes after everolimus-eluting and paclitaxel-eluting stent implantation: pooled analysis from the SPIRIT III and SPIRIT IV clinical trials.
Hermiller JB; Sudhir K; Applegate RJ; Rizvi A; Wang J; Gordon PC; Yaqub M; Cao S; Ferguson JM; Smith RS; Sood P; Stone GW
EuroIntervention; 2012 May; 8(1):87-93. PubMed ID: 22580252
[TBL] [Abstract][Full Text] [Related]
4. Very late coronary stent thrombosis of a newer-generation everolimus-eluting stent compared with early-generation drug-eluting stents: a prospective cohort study.
Räber L; Magro M; Stefanini GG; Kalesan B; van Domburg RT; Onuma Y; Wenaweser P; Daemen J; Meier B; Jüni P; Serruys PW; Windecker S
Circulation; 2012 Mar; 125(9):1110-21. PubMed ID: 22302840
[TBL] [Abstract][Full Text] [Related]
5. Five-year long-term clinical follow-up of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with de novo coronary artery disease: the SPIRIT II trial.
Onuma Y; Miquel-Hebert K; Serruys PW;
EuroIntervention; 2013 Jan; 8(9):1047-51. PubMed ID: 23339811
[TBL] [Abstract][Full Text] [Related]
6. Performance of everolimus-eluting versus paclitaxel-eluting coronary stents in small vessels: results from the SPIRIT III and SPIRIT IV clinical trials.
Ito H; Hermiller JB; Yaqub M; Newman W; Sood P; Wang JC; Cannon L; Maddux JE; Sudhir K; Stone GW
J Interv Cardiol; 2011 Dec; 24(6):505-13. PubMed ID: 21919955
[TBL] [Abstract][Full Text] [Related]
7. Stent thrombosis with everolimus-eluting stents: meta-analysis of comparative randomized controlled trials.
Palmerini T; Kirtane AJ; Serruys PW; Smits PC; Kedhi E; Kereiakes D; Sangiorgi D; Bacchi Reggiani L; Kaiser C; Kim HS; De Waha A; Ribichini F; Stone GW
Circ Cardiovasc Interv; 2012 Jun; 5(3):357-64. PubMed ID: 22668554
[TBL] [Abstract][Full Text] [Related]
8. Predictors of death or myocardial infarction, ischaemic-driven revascularisation, and major adverse cardiovascular events following everolimus-eluting or paclitaxel-eluting stent deployment: pooled analysis from the SPIRIT II, III, IV and COMPARE trials.
Kereiakes DJ; Smits PC; Kedhi E; Parise H; Fahy M; Serruys PW; Stone GW
EuroIntervention; 2011 May; 7(1):74-83. PubMed ID: 21550906
[TBL] [Abstract][Full Text] [Related]
9. Stent Thrombosis and Dual Antiplatelet Therapy Interruption With Everolimus-Eluting Stents: Insights From the Xience V Coronary Stent System Trials.
Généreux P; Rutledge DR; Palmerini T; Caixeta A; Kedhi E; Hermiller JB; Wang J; Krucoff MW; Jones-McMeans J; Sudhir K; Simonton CA; Serruys PW; Stone GW
Circ Cardiovasc Interv; 2015 May; 8(5):. PubMed ID: 25940520
[TBL] [Abstract][Full Text] [Related]
10. Short- and long-term outcomes with drug-eluting and bare-metal coronary stents: a mixed-treatment comparison analysis of 117 762 patient-years of follow-up from randomized trials.
Bangalore S; Kumar S; Fusaro M; Amoroso N; Attubato MJ; Feit F; Bhatt DL; Slater J
Circulation; 2012 Jun; 125(23):2873-91. PubMed ID: 22586281
[TBL] [Abstract][Full Text] [Related]
11. Clinical and angiographic outcomes of elderly patients treated with everolimus-eluting versus paclitaxel-eluting stents: three-year results from the SPIRIT III randomised trial.
Hermiller JB; Nikolsky E; Lansky AJ; Applegate RJ; Sanz M; Yaqub M; Sood P; Cao S; Sudhir K; Stone GW
EuroIntervention; 2011 Jul; 7(3):307-13. PubMed ID: 21729832
[TBL] [Abstract][Full Text] [Related]
12. Twelve-month clinical outcomes of everolimus-eluting stent as compared to paclitaxel- and sirolimus-eluting stent in patients undergoing percutaneous coronary interventions. A meta-analysis of randomized clinical trials.
Cassese S; Piccolo R; Galasso G; De Rosa R; Piscione F
Int J Cardiol; 2011 Jul; 150(1):84-9. PubMed ID: 21315461
[TBL] [Abstract][Full Text] [Related]
13. Four-year clinical follow-up of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with de novo coronary artery lesions: the SPIRIT II trial.
Garg S; Serruys PW; Miquel-Hebert K;
Catheter Cardiovasc Interv; 2011 Jun; 77(7):1012-7. PubMed ID: 20824770
[TBL] [Abstract][Full Text] [Related]
14. SPIRIT IV trial design: a large-scale randomized comparison of everolimus-eluting stents and paclitaxel-eluting stents in patients with coronary artery disease.
Nikolsky E; Lansky AJ; Sudhir K; Doostzadeh J; Cutlip DE; Piana R; Su X; White R; Simonton CA; Stone GW
Am Heart J; 2009 Oct; 158(4):520-526.e2. PubMed ID: 19781409
[TBL] [Abstract][Full Text] [Related]
15. Everolimus-eluting stents and paclitaxel-eluting stents in patients presenting with myocardial infarction: insights from the two-year results of the COMPARE prospective randomised controlled trial.
Kedhi E; Gomes M; Joesoef KS; Wassing J; Goedhart D; McFadden E; Smits PC
EuroIntervention; 2012 Apr; 7(12):1376-85. PubMed ID: 22266771
[TBL] [Abstract][Full Text] [Related]
16. Everolimus-eluting versus paclitaxel-eluting stents for treatment of bare metal stent restenosis.
Almalla M; Schröder JW; Pross V; Stegemann E; Marx N; Hoffmann R
Am J Cardiol; 2011 Aug; 108(4):518-22. PubMed ID: 21624553
[TBL] [Abstract][Full Text] [Related]
17. Should duration of dual antiplatelet therapy depend on the type and/or potency of implanted stent? A pre-specified analysis from the PROlonging Dual antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY (PRODIGY).
Valgimigli M; Borghesi M; Tebaldi M; Vranckx P; Parrinello G; Ferrari R;
Eur Heart J; 2013 Mar; 34(12):909-19. PubMed ID: 23315904
[TBL] [Abstract][Full Text] [Related]
18. A randomized controlled trial in second-generation zotarolimus-eluting Resolute stents versus everolimus-eluting Xience V stents in real-world patients: the TWENTE trial.
von Birgelen C; Basalus MW; Tandjung K; van Houwelingen KG; Stoel MG; Louwerenburg JH; Linssen GC; Saïd SA; Kleijne MA; Sen H; Löwik MM; van der Palen J; Verhorst PM; de Man FH
J Am Coll Cardiol; 2012 Apr; 59(15):1350-61. PubMed ID: 22341737
[TBL] [Abstract][Full Text] [Related]
19. 2-year patient-related versus stent-related outcomes: the SORT OUT IV (Scandinavian Organization for Randomized Trials With Clinical Outcome IV) Trial.
Jensen LO; Thayssen P; Christiansen EH; Tilsted HH; Maeng M; Hansen KN; Kaltoft A; Hansen HS; Bøtker HE; Krusell LR; Ravkilde J; Madsen M; Thuesen L; Lassen JF;
J Am Coll Cardiol; 2012 Sep; 60(13):1140-7. PubMed ID: 22958957
[TBL] [Abstract][Full Text] [Related]
20. Randomized comparison of everolimus- and paclitaxel-eluting stents: pooled analysis of the 2-year clinical follow-up from the SPIRIT II and III trials.
Onuma Y; Serruys PW; Kukreja N; Veldhof S; Doostzadeh J; Cao S; Stone GW;
Eur Heart J; 2010 May; 31(9):1071-8. PubMed ID: 20118171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
